



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/344,189	06/24/1999	CHARLES E. ROGLER	0342/1D888US	8764

7590

06/25/2003

DARBY & DARBY  
ANNE E ZITRON PH D  
805 THIRD AVENUE  
NEW YORK, NY 10022

EXAMINER

PARAS JR, PETER

ART UNIT

PAPER NUMBER

1632

28

DATE MAILED: 06/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/344,189	ROGLER, CHARLES E.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Peter Paras, Jr.	1632	

All participants (applicant, applicant's representative, PTO personnel):

(1) Peter Paras, Jr. (3) \_\_\_\_\_

(2) Mitch Bernstein. (4) \_\_\_\_\_

Date of Interview: 24 June 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: see attached interview agenda and proposed claims.

Claim(s) discussed: \_\_\_\_\_

Identification of prior art discussed: \_\_\_\_\_

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

**PETER PARAS**  
**PATENT EXAMINER**



Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: All the rejections of record were discussed. With regard to the enablement rejection Applicant's representative argued that it would not require undue experimentation to practice the invention as claimed because the specification teaches that hemizygous or homozygous uPA transgenic mice can be used. Since the claimed invention can be practiced with only two possible mice Applicant's representative asserted that it would not have required undue experimentation to practice the invention as claimed. .

**DARBY &  
DARBY**Professional  
Corporation805 Third Avenue  
New York, NY 10022  
Tel: (212) 527-7700  
Fax: (212) 753-6237**INTELLECTUAL PROPERTY LAW****FILE #:** 3368/1D888-US1**DATE:** June 23, 2003

**FROM:** Mitchell Bernstein, Ph.D. **E-MAIL:** mbernstein@darbylaw.com  
**PHONE:** (212) 527-7708  
**NO. OF PAGES:** 11

CONFIDENTIAL		
703-746-5304	Examiner Peter Paras, Jr. USPTO, GAU 1632	No

**COMMENTS:**

Examiner Paras,

Further to our earlier conversation, I have attached form PTOL-413A and a set of draft claims. I will call you tomorrow at 2:00 PM, as we agreed.

FYI: The form PTOL-413A you attempted to send was not part of the fax I received. I obtained the attached form directly from the USPTO web site.

—Mitch Bernstein

**PLEASE RETURN TO MITCHELL BERNSTEIN, PH.D.**

\* IF YOU DO NOT RECEIVE ALL PAGES, PLEASE TELEPHONE US IMMEDIATELY AT (212) 527-7774

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE SO THAT WE CAN ARRANGE FOR THE RETRIEVAL OF THIS DOCUMENT AT NO COST TO YOU. THANK YOU.

M:\3368\1d888\00016252.DOC

Received from &lt; &gt; at 6/23/03 12:21:24 PM [Eastern Daylight Time]

PTOL-413A (05-03)

Approved for use through 10/1/2000. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## Applicant Initiated Interview Request Form

Application No.: 09/344,189 First Named Applicant: Charles E. ROGLER  
 Examiner: Peter Paras, Jr. Art Unit: 1632 Status of Application: Non-final rej.

## Tentative Participants:

(1) Examiner Paras (2) Mitchell Bernstein

(3) \_\_\_\_\_ (4) \_\_\_\_\_

Proposed Date of Interview: 6/24/03 Proposed Time: 2:00 (AM/PM)

## Type of Interview Requested:

(1) ☒ Telephonic (2) ☐ Personal (3) ☐ Video Conference

Exhibit To Be Shown or Demonstrated: ☒ YES ☐ NO

If yes, provide brief description: \_\_\_\_\_

Draft claims

## Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) Rej.	Cl. 1-48	Mercer et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Continuation Sheet Attached

Brief Description of Arguments to be Presented: Amended claims overcome alleged

indefiniteness; specification enables full scope of claims; Genentech v

Novo Nordisk does not support rejection for lack of enablement.

An interview was conducted on the above-identified application on \_\_\_\_\_

## NOTE:

This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

*Mitchell Bernstein*  
 (Applicant/Applicant's Representative Signature)

\_\_\_\_\_  
 (Examiner/SPE Signature)

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

Claim 1 (Currently amended):

A method of making a chimeric mouse, comprising:

a. creating an immunetolerant mouse lacking functional T and B cells and having a genome which comprises a urokinase-type plasminogen activator (uPA) gene, expression of said uPA gene resulting in liver degeneration; and

b. repopulating the parenchyma of the degenerated liver by transplanting xenogenic mammalian hepatocytes that are a natural host for infection with one or more compatible hepatitis virus into said liver; thereby making said chimeric mouse

transplanting xenogenic mammalian hepatocytes to repopulate the parenchyma of the degenerated liver, said xenogenic mammalian hepatocytes being infected with at least one compatible mammalian hepatitis virus.

Claim 2 (Currently amended): The method of claim 1, which further comprising comprises infecting the xenogenic mammalian hepatocytes with hepatitis virus prior to said transplanting.

Claim 3 (Currently amended): The method of claim 1, which further comprising comprises infecting the xenogenic mammalian hepatocytes with hepatitis virus following said repopulation.

Claim 4 (Currently amended): The method of claim 1, which comprises selecting wherein the xenogenic mammalian hepatocytes are selected from the group consisting of human, chimpanzee, baboon, wooly monkey, ground squirrel, and woodchuck hepatocytes.

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

Claim 5 (Original): The method of claim 1, wherein the compatible mammalian hepatitis virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

Claim 6 (Original):

The method of claim 1, wherein the immunetolerant mouse which has a degenerated liver is created by:

- a. crossing a hemizygous or homozygous urokinase-type plasminogen activator (uPA) transgenic mouse with a homozygous Recombination Activation Gene 2 (RAG-2) knockout mouse to generate F1 uPA hemizygous, RAG-2 hemizygous sibling mice; and
- b. crossing the F1 mouse to another sibling F1 mouse or to a RAG2 homozygous mouse to generate a uPA hemizygous or homozygous, RAG2 homozygous (uPA/RAG2) F2 mouse.

Claim 7 (Original): The method of claim 6, wherein the xenogenic mammalian hepatocyte is from a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

Claim 8 (Previously amended): A chimeric mouse model system for hepatitis comprising an immunetolerant mouse lacking functional T and B cells having a degenerated liver parenchyma due to expression of a urokinase-type plasminogen activator (uPA) gene present in the genome of said immunetolerant mouse, said degenerated liver being repopulated

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

with transplanted xenogenic mammalian hepatocytes that are infected with a compatible mammalian hepatitis virus.

Claim 9 (Original): The chimeric mouse model system of claim 8, wherein the xenogenic mammalian hepatocytes are infected with hepatitis virus prior to said transplantation.

Claim 10 (Original): The chimeric mouse model system of claim 8, wherein the xenogenic mammalian hepatocytes are infected with hepatitis virus following said repopulation.

Claim 11 (Original): The chimeric mouse model system of claim 8, wherein the xenogenic mammalian hepatocytes is a member selected from the group consisting of human, chimpanzee, baboon, wooly monkey, ground squirrel, and woodchuck hepatocytes.

Claim 12 (Original): The chimeric mouse model system of claim 8, wherein the compatible mammalian hepatitis virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

Claim 13 (Currently amended): The chimeric mouse model system of claim 8, wherein the immunetolerant mouse having degenerated liver parenchyma is hemizygous or homozygous for said urokinase-type plasminogen activator (uPA) gene and is homozygous for the  $\alpha$  Recombination Activation Gene 2 (RAG-2) knockout gene.

Claim 14 (Original): The chimeric mouse model system of claim 13, wherein the source of the xenogenic mammalian hepatocytes is a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

Claim 15 (Currently amended):

A method for screening a test compound for anti-viral activity, comprising:



Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

- a. administering said test compound to an immunetolerant chimeric mouse lacking functional T and B cells which has a degenerated liver parenchyma due to expression of a urokinase-type plasminogen activator (uPA) gene present in the genome of said immunetolerant chimeric mouse, said degenerated liver being repopulated with transplanted xenogenic mammalian hepatocytes that are infected with at least one compatible mammalian hepatitis virus; and
- b. assaying the level of replication of the virus; thereby screening said test compound for anti-viral activity.

Claim 16 (Original): The method of claim 15, wherein the mammalian virus is at least one hepatitis virus.

Claim 17 (Original): The method of claim 15, which comprises comparing the level of viral replication in said mouse and in a control mouse which has not been administered the test compound.

Claim 18 (Original): The method of claim 15, which comprises infecting the xenogenic mammalian hepatocytes with the compatible mammalian virus prior to said transplanting.

Claim 19 (Original): The method of claim 16, which comprises infecting the xenogenic mammalian hepatocytes with the compatible mammalian virus following said repopulating step.

Claims 20 (Original): The method of claim 15, which comprises selecting the xenogenic mammalian hepatocyte from the group consisting of human, chimpanzee, baboon, woolly monkey, ground squirrel, and woodchuck hepatocytes.

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

Claim 21 (Original): The method of claim 15, wherein the compatible mammalian virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

Claim 22 (Currently amended): The method of claim 15, wherein the immunetolerant mouse which has a degenerated liver is hemizygous or homozygous for said urokinase-type plasminogen activator (uPA) gene and homozygous for the a Recombination Activation Gene 2 (RAG-2) knockout gene.

Claim 23 (Original): The method of claim 22, wherein the source of the xenogenic mammalian hepatocytes is a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

Claim 24 (Original): The method of claim 15, wherein the antiviral compound is a member selected from the group consisting of interferons, cytokines, interleukins, growth factors, hormones, nucleoside analogues, and antisense DNA/RNA.

Claim 25 (Currently amended):

A method for screening a test compound for anti-cancer activity, comprising:

- a. administering said test compound to immunetolerant chimeric mice lacking functional T and B cells which have degenerated liver parenchyma due to expression of a urokinase-type plasminogen activator (uPA) gene present in the genome of said immunetolerant chimeric mice that is repopulated with transplanted xenogenic mammalian hepatocytes that are infected with at least one compatible mammalian hepatitis virus capable of causing hepatocellular carcinoma in said xenogenic hepatocytes; and

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

b. assaying said mice for the development of hepatocellular carcinoma virus; thereby screening said test compound for anti-cancer activity.

Claim 26 (Original): The method of claim 25, which comprises comparing the presence of unique viral DNA integrations in the liver of said mouse and in a control mouse which has not been administered the test compound.

Claim 27 (Original): The method of claim 25, wherein the chimeric mouse has precancerous or malignant cancerous hepatic tissue and wherein the development of hepatocellular carcinomas is assayed by monitoring for the prevention of the development of cancerous tissue from precancerous tissue or the amelioration of the malignant cancerous tissue.

Claim 28 (Original): The method of claim 27, which comprises comparing the assay in the chimeric mouse with the same assay carried out in a control mouse which has not been administered the test compound.

Claim 29 (Original): The method of claim 25, which comprises infecting the xenogenic mammalian hepatocytes with a hepatitis virus prior to said transplantation step.

Claim 30 (Original): The method of claim 25, which comprises infecting the xenogenic mammalian hepatocytes with hepatitis virus prior to said transplanting step.

Claim 31 (Original): The method of claim 25, which comprises infecting the xenogenic mammalian hepatocytes are infected with hepatitis virus following said repopulating step.

Claim 32 (Original): The method of claim 25, which comprises selecting the xenogenic mammalian hepatocyte from the group consisting of human, chimpanzee, baboon, woolly monkey, ground squirrels and woodchuck hepatocytes.

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

Claim 33 (Original): The method of claim 25, wherein the compatible mammalian hepatitis virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

Claim 34 (Currently amended): The method of claim 25, wherein the immunetolerant mouse which has a degenerated liver is hemizygous or homozygous for said urokinase-type plasminogen activator (uPA) gene and homozygous for the a Recombination Activation Gene 2 (RAG-2) knockout gene.

Claim 35 (Original): The method of claim 33, wherein the source of the xenogenic mammalian hepatocytes is a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

Claim 36 (Original): The method of claim 25, wherein the anticancer compound is a member selected from the group consisting of interferons, cytokines, interleukins, growth factors, hormones, nucleoside analogues, and antisense DNA/RNA.

Claim 37 (Currently amended):

A method of making a chimeric mouse, comprising:

- a. creating an immunetolerant mouse, said immunetolerant mouse lacking functional T and B cells and having a genome which comprises a urokinase-type plasminogen activator (uPA) gene, expression of said uPA gene resulting in liver degeneration; and
- b. repopulating the parenchyma of the degenerated liver by transplanting xenogenic mammalian hepatocytes that are a natural host for infection with one or more compatible hepatitis virus into said liver; thereby making said chimeric mouse.

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

Claim 38 (Currently amended): A chimeric mouse model system for hepatitis comprising an immunetolerant mouse lacking functional T and B cells,  
said immunetolerant mouse having a degenerated liver parenchyma due to expression of a urokinase-type plasminogen activator (uPA) gene present in the genome of said immunetolerant mouse, and  
said degenerated liver is being repopulated with transplanted xenogenic mammalian hepatocytes that are a natural host for infection with one or more compatible hepatitis virus.

Claim 39 (Currently amended):

A method of making a chimeric mouse, comprising:

- a. creating an immunetolerant mouse, said immunetolerant mouse having a degenerated liver due to expression of a urokinase-type plasminogen activator (uPA) gene and lacking functional T and B cells, said uPA gene being present in the genome of said immunetolerant mouse; and
- b. transplanting human hepatocytes having at least 80% viability by intrasplenic injection to repopulate the parenchyma of the degenerated liver; thereby making said chimeric mouse.

Claim 40 (Previously added): The method of claim 39 wherein said immunetolerant mouse is about 10-14 days old at the time of transplanting said human hepatocytes.

Claim 41 (Previously added): The method of claim 40 wherein the transplanted human hepatocytes reconstitute approximately 10% of the degenerated liver.

Docket No. 3368/1D888-US1  
Serial No. 09/344,189

**Draft Claims (6.23.2003)**

Claim 42 (Previously added): The method of claim 1 wherein said uPA gene encodes secreted uPA.

Claim 43 (Previously added): The chimeric mouse model system of claim 8 wherein said uPA gene encodes secreted uPA.

Claim 44 (Previously added): The method of claim 15 wherein said uPA gene encodes secreted uPA.

Claim 45 (Previously added): The method of claim 25 wherein said uPA gene encodes secreted uPA.

Claim 46 (Previously added): The method of claim 37 wherein said uPA gene encodes secreted uPA.

Claim 47 (Previously added): The chimeric mouse model system of claim 38 wherein said uPA gene encodes secreted uPA.

Claim 48 (Previously added): The method of claim 39 wherein said uPA gene encodes secreted uPA.